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Abstract
Background: Disclosure of financial conflicts of interest (COI) is intended to help reviewers assess the impact of potential
bias on the validity of research results; however, there have been no empiric assessments of how reviewers understand and
use disclosures in article evaluation. We investigate reviewers’ perceptions of potential bias introduced by particular author
disclosures, and whether reviewer characteristics are associated with a greater likelihood of perceiving bias.
Methodology/Principal Findings: Of the 911 active reviewers from the Annals of Emergency Medicine, 410 were randomly
selected and invited to complete our web-based, 3-part survey. We completed descriptive analysis of all survey responses
and compared those responses across reviewer characteristics using 262 analyses and the Fisher exact test. We had a
response rate of 54%. The majority of reviewers surveyed reported a high level of skepticism regarding financial
relationships between authors and industry without a clear or consistent translation of that skepticism into the self-reported
actions that characterize manuscript assessment. Only 13% of respondents believed physician consultants authoring articles
based on company data are likely to have unlimited data access. 54% believed that bias most likely exists with any
honorarium, regardless of monetary amount. Between 46% and 64%, depending on the type of financial relationship
disclosed, reported that their recommendation for publication remains unchanged. Respondents reporting personal
financial ties to industry were less likely to perceive bias in industry relationships and less likely to believe that bias exists
with any monetary amount of honoraria.
Conclusions: We recommend that the monetary amount of all financial relationships be reported with manuscript
submissions, lead authors certify that they have unrestricted access to data, and reviewers disclose any financial ties to
industry whether or not they are related to the manuscript under review. Further research is required to better understand
reviewers’ perceptions of financial relationships between authors and industry in order to develop clear and consistent
guidelines for incorporating the perception of potential bias into manuscript assessments.
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Introduction
Disclosure of physicians’ financial relationships with pharma-
ceutical companies is a cornerstone of conflict of interest (COI)
policies [1]. Media revelations of financial COI in clinical
researchers, as well as U.S. Congressional investigations, have
highlighted the need to deal with such conflicts. Disclosing
authors’ COI is intended to help reviewers, editors, and readers
assess the likelihood of bias and the potential impact on the validity
of the research results and conclusions. For this intention to be
manifest, the scientific community expects that reviewers and
readers interpret disclosures accurately and consistently, and that
they translate their interpretations into an ability to recognize and
compensate for potential bias. These assumptions of peer
reviewers in particular, however, have not been assessed
empirically. A better understanding of how peer reviewers
incorporate disclosures of financial conflicts into the assessment
of manuscripts that they review could improve the peer review
process and thus enhance the validity of research publications.
We conducted a survey as an initial step in investigating how
journal peer reviewers interpret various financial relationships
between industry and authors and how their interpretations
influence their approach to manuscripts. Our research questions
were: How do peer reviewers interpret disclosures that an author
serves on a speakers bureau or is a consultant for industry? Do
reviewers view those roles as sources of potential bias for authors,
and to what degree? How do reviewers incorporate their
perceptions of those roles into reviews of submitted manuscripts?
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26900Are reviewers’ personal ties to industry or the number or quality of
their reviews associated with a greater likelihood of perceiving bias
or altering the appraisal of manuscripts?
Methods
Our study was conducted at Annals of Emergency Medicine, which
ranks in the top 11% among 6,620 science and medical journals by
number of citations and is the leading emergency medicine journal
by impact factor [2]. The vast majority of the papers submitted for
review by the academic clinicians and clinical researchers that
make up the reviewer pool are original clinical research. Annals
conducts double-blinded reviews and requires COI disclosures for
authors, reviewers, and editors as recommended by the Interna-
tional Committee of Medical Journal Editors (ICMJE) (http://
www.icmje.org/ethical_4conflicts.html; http://www.annemergmed.
com/content/instauth#conflict). Each review receives a quality
rating from the editor supervising the manuscript using a single,
global, 5 point scale [3]. This quality rating is virtually identical to
the rating scale validated at the British Medical Journal [4], and its
reliability has been previously reported [5]. The rating scale has also
been found to moderately correlate (R=0.53) with a reviewer’s
ability to detect deliberate errors in a test manuscript [5].
We developed a 29-question, 3-part, web-based survey,
administered through surveymonkey.com. The initial survey was
reviewed and tested with editorial colleagues, who also have
extensive experience as reviewers, after which final revisions to the
content were made for clarity and convenience. The responses to
the survey questions were confidentially linked to the Annals
database, which tracks reviewer experience and quality rating for
all reviews over the past 14 years. The initial questions were
designed to assess baseline reviewer knowledge and perceptions of
the activities and benefits of two specific potential conflicts
commonly disclosed: serving on a speakers bureau and acting as
a consultant. In the second portion of the survey, we elicited
reactions to hypothetical manuscripts, which included either one
of these two COI disclosures or disclosures such as stock
ownership, direct financial payments and research sponsorship.
Finally, we gathered information regarding participants’ personal
ties to industry, experience in peer-review, and teaching roles
(Survey instrument Appendix A).
Participants
We invited a sample of 410 reviewers randomly selected from
the database of 911 Annals of Emergency Medicine active reviewers,
those completing at least one review in the past two years. As our
objective was primarily descriptive, we did not undertake power
calculations. Selected reviewers were contacted by email with a
request to participate in a survey evaluating the role of financial
disclosures in the peer-review process. Participants were informed
that we would associate survey responses with data from the Annals
files on reviewer experience, coding the associated data for
anonymity. Emails were sent to each potential participant at the
address they provided for journal reviews; if no response was
received, two further attempts were made to contact the recipient
while confirming that a correct email address was being used.
Analysis
Our planned analysis was primarily descriptive. We present the
frequencies of responses on a five-point Likert scale, condensing the
scale into positive (very likely and likely), negative (unlikely and very
unlikely), and don’t know responses where possible for simplicity.
We compared respondents to non-respondents and to all Annals
reviewers in terms of reviewer age, gender, years since completion
of residency, number of reviews completed and reviewer quality
rating, as defined above. We gathered professional characteristics
of the reviewers, including years since residency, hours per week of
didactic teaching, reviewer quality rating, and total number of
reviews completed. We evaluated whether these characteristics
were associated with an increased frequency in reviewers’
perception that a percent income threshold for bias exists;
reviewers’ knowledge of the activities expected of speakers bureau
members and consultants; reviewers’ interpretation of the
likelihood of bias associated with guarantees of future collaborative
projects, sponsorship of research, stock options or direct financial
payments; and reviewers’ self reported incorporation of disclosures
into article assessment (reading more carefully, change in
perception of the article’s credibility, change in likelihood to
recommend for publication). Finally, we examined whether
reviewers with financial ties to industry, defined as those who
receive any honoraria, work as a consultant, or own stock or
equity, are more likely to endorse a potential for bias in industry-
related financial ties. Participants who responded, ‘‘don’t know,’’
were not included in the 262 analyses.
We used SAS 9.2 (SAS Institute Inc, Cary, NC, USA) to
calculate Chi square statistics or, where necessary due to sample
size, Fisher exact tests, setting a significance level of 0.05. We did
not apply the Bonferoni correction for multiple comparisons. IRB
approval from UCSF was obtained and each participant was asked
explicitly for consent before accessing the survey questions.
Results
Of the 410 invited reviewers, eight were excluded because the
original email address was not correct and could not be validated.
218 reviewers completed responses to the survey (response rate of
54%). Table 1 shows the characteristics of the sample; there were
no differences between respondents and non-respondents [data
not shown].
Respondent perceptions of pharmaceutical company
speakers bureaus
A large majority of respondents believed that companies exert
various types of influence over the content of lectures given by
physicians on the company’s speakers bureau, including provision
of text and slides (88%), consistency of the medical content with
marketing messages (85%), and selective re-invitation of speakers
(79%) (Figure 1). Respondents without financial ties to industry (as
defined in our methods) were significantly more likely than
respondents with ties to agree that the content of speakers bureau
talks is consistent with the company’s marketing message; (99% vs.
88%, Fisher’s exact test p=0.01).
The FDA requires that talks sponsored by a drug company
mention only FDA-approved uses. However, 35% of respondents
Table 1. Participant characteristics.
Descriptor Total n
Male 217 151 (69%)
Mean Age, years 176 48 (SD 8.4, range 28–69)
Median years since completion of residency 183 18 (range 0–40)
Median number of reviews completed 194 11 (range 1–80)
Mean reviewer rating (5 point scale, 5
outstanding)
194 3.8 (SD 0.62)
doi:10.1371/journal.pone.0026900.t001
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bureau presentations mention only FDA-approved indications,
while an additional 14% did not know. More reviewers without
financial ties than those with ties thought it unlikely that the
company must make that assurance (51% vs. 34%, p=0.04,
Fisher’s exact).
Respondent perceptions of consultant activities for
pharmaceutical companies
A majority of respondents believed that companies exert
influences over the content of articles authored by physicians
working as consultants (Figure 2). These influences include a
belief that consultants have limited access to data (74%),
collaborate with company ghostwriters (53%), have goals
aligned with the company’s marketing message (66%), and are
reluctant to jeopardize a future working relationship with the
company (73%). Reviewers without any financial ties to industry
were significantly more likely to believe that consultants act as a
liaison between community physicians and the pharmaceutical
company to promote the company’s products (84% vs. 68%
p=0.03, Fisher’s exact). In addition, significantly more
reviewers without ties believed that a reluctance to jeopardize
the working relationship is likely (87% vs. 74% p=0.05, Fisher’s
exact).
There were no significant differences in reviewers’ responses to
questions regarding speakers bureaus or consulting based on years
since residency, hours per week of teaching, reviewer quality
rating, or number of total reviews completed.
Respondent perceptions of potential bias
Fifty-four percent of respondents believed that any level of
honoraria from a pharmaceutical company, no matter how small,
would most likely bias the author’s judgment. Respondents
without financial ties to industry were more likely than
respondents with ties to believe this (67% vs. 33% Fisher’s exact
p=0.02). Eighty-four percent of respondents reported that bias
was most likely to exist if an author received honoraria totaling up
to 10% of professional income (Figure 3). With regard to specific
types of consulting relationships, 89% of respondents believed that
research support is likely to influence a consultant’s judgment
when authoring an article, and 67% felt similarly about direct
financial payments agreed upon in advance.
Impact on review of submitted manuscripts
Ninety-nine percent of respondents reported reading the
financial disclosure statement, with 66% reading it before reading
the manuscript. The majority of respondents would read a
manuscript more carefully and consider the credibility diminished
if the lead author disclosed serving on the speakers bureau, acting
as a consultant, or owning stock in the company who
manufactured the medication being studied. The majority then
reported that their recommendation for publication would remain
Figure 1. Respondent perceptions of arrangements in pharmaceutical company speakers bureaus.
doi:10.1371/journal.pone.0026900.g001
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flaws were identified (Figure 4).
Discussion
Because of highly publicized cases of financial conflicts of
interest leading to a lack of scientific integrity in published articles
[6], journals have been urged to adopt comprehensive COI
disclosure requirements for authors [7]. For disclosure to be
effective, reviewers must be able to critically assess to what extent a
conflict of interest exists, to judge the impact that COI may have
on the validity of a submitted manuscript, and to incorporate those
judgments into a recommendation regarding publication. In one
of the only empirical studies of the influence of COI disclosures on
readers’ perceptions of an article, Schroter et al [8] completed a
randomized control trial in which 900 British Medical Journal
(BMJ) readers were provided an article with one of three possible
COI disclosures. The ‘‘financial statement’’ declared the authors
to be employees or owners of stock,’’ the ‘‘grants statement,’’
declared the authors to have received research funding and the
‘‘none statement’’ declared no COI. The importance, relevance,
validity, and believability ratings of the articles were significantly
lower for the article in which ‘‘authors are employees and
potentially own stock’’ than in the ‘‘none declared’’ group.
Building on these findings but focusing our population of interest
on peer reviewers, who are directly involved with decisions
regarding the publication of research in contrast to the general
readership, we carried out an empirical study with experienced
reviewers of medical research from a journal that has an explicit
COI policy for authors, reviewers, and editors. We had 4 major
findings.
First, the vast majority of respondents perceive of roles on
speakers bureaus or as consultants to be aligned with company
marketing goals. Even activities condemned by the International
Committee of Medical Journal Editors (ICMJE), World Associa-
tion of Medical Editors (WAME), and Committee on Publication
Ethics (COPE), such as ghost writing or authoring articles with
only limited access to data, are believed to be likely occurrences
[6].
Second, the majority of our respondents did not believe that the
bias attributed to these roles has a minimum monetary threshold.
Over one-half of respondents believe that bias most likely exists
with any honorarium, regardless of monetary amount; while over
90% of respondents believe that bias most likely exists even if
authors received up to only 17% of income from a pharmaceutical
company.
Third, in contrast to respondents without financial ties, those
who disclosed having any personal financial ties to industry were
less likely to attribute bias to speakers bureau and consultant roles,
and less likely to believe that honoraria of any monetary value, no
matter how small, introduces bias (Table 2). There are several
possible explanations for this discrepancy between respondents
with and without financial ties to industry.
Respondents who serve on speakers bureaus or act as
consultants may have found, in their direct experience, that
companies did not expect their lectures to be aligned with
Figure 2. Respondent perceptions of consultant activities for pharmaceutical companies.
doi:10.1371/journal.pone.0026900.g002
Peer Reviewer Perceptions of COI Disclosures
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26900marketing goals and that access to data was unlimited. In addition,
these reviewers may have more concrete, inside knowledge about
the actual activities and benefits of working as a consultant or on a
speakers bureau. This interpretation is supported by our finding
that reviewers with personal financial ties to industry were more
likely to accurately state that companies must ensure speakers
bureau presentations mention only FDA approved uses. However,
our study can neither confirm nor refute this explanation.
Basic psychological research suggests ‘‘that when individuals
stand to gain by reaching a particular conclusion, they tend to
unconsciously and unintentionally weigh evidence in a biased
fashion that favors that conclusion.’’ [1] Based on this psycholog-
ical vulnerability to unintentional bias, the discrepancy we found
between those with and without personal financial ties to industry
may be present because respondents with financial relationships to
pharmaceutical companies project their belief that they are
immune to undue influence or discount the potential influence
in order to prevent cognitive dissonance. This interpretation raises
the concern that reviewers with personal ties to industry, regardless
of the relevance to a particular article under review, may
themselves be vulnerable to minimizing the possible effects of
financial relationships with industry to prevent cognitive disso-
nance when assessing an author’s potential of bias.
Finally, most respondents reported that they read articles more
carefully and consider the credibility diminished if the author
discloses a financial relationship with the manufacturer of the
study drug. About two-thirds of respondents would not change
their recommendation regarding publication if they found no
design or statistical concerns regardless of the author’s financial
disclosures. Thus reviewers express skepticism of industry
relationships but report no overt discrimination against industry-
funded manuscripts; rather, their answers suggest that they base
their decision for publication on the perceived scientific merit of
the manuscript.
Although this is reassuring, it should be interpreted in light of
possible social desirability bias as the results rely on self-reported
attitudes and behaviors. Additionally, it should be interpreted
with an understanding of reviewers’ known limitations, including
reviewers’ variable capacity to find statistical and design flaws
within manuscripts under review. In a study using a fictitious
manuscript with purposeful errors, 68% of reviewers did not
realize that the conclusions of the work were not supported by the
results [9]. Similarly, a subsequent investigation reported that
reviewers found only an average of three out of nine, major,
deliberately induced errors in papers manipulated for the study
[10]. Although our reviewers reported reading papers more
carefully and critically, it remains unknown whether after reading
author disclosures of financial relationships to the study sponsor
or drug manufacturer, they are in fact better able to detect flaws
in a manuscript and to recommend revisions to mitigate those
flaws.
Limitations
Our response rate was 54% despite multiple attempts to contact
potential participants via email. Nevertheless, no significant
differences were found between responders and non-responders
Figure 3. Cumulative percent of respondents who report the threshold for physician income from pharmaceutical companies
beyond which an author’s judgment is most likely biased. N=188.
doi:10.1371/journal.pone.0026900.g003
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experience, reviewer volume, review quality rating, age, or gender.
Even in the unlikely situation that all the non-respondents had
answered differently than responders, there would still have been a
large proportion of reviewers sharing the views reported here.
As with any survey relying on self-reported attitudes and
behaviors, stated preferences are highly subject to social
desirability bias. Because of the time, effort, and logistics required,
recruiting and randomizing reviewers to review fictitious manu-
scripts that reveal or omit conflict disclosures was not feasible,
Figure 4. Impact of disclosures on respondents’ review of manuscripts.
doi:10.1371/journal.pone.0026900.g004
Table 2. Comparison analysis of reviewers with or without personal financial ties to industry.
Percentage of reviewers of the total with or
without ties responding that the statements
below are likely or very likely to be true
N=Total
reviewers without
financial ties
N=Total
reviewers with
financial ties X2 p Fisher p
Only FDA indications mentioned in physician speakers lectures 80 (49%) 62 (66%) 4.3 0.04 0.04
Company provides the physician speaker with the prescribing
patterns of the audience
65 (71%) 49 (51%) 4.6 0.03 0.03
Presentation expected to be consistent with the company’s
marketing message
82 (99%) 66 (88%) 7.6 0.006 0.01
Consultant provides the company with the names of
community physician opinion leaders
82 (98%) 61 (89%) 4.8 0.028 0.04
Consultant acts as a liaison with community physicians
with the goal of promoting the company’s products
82 (84%) 62 (68%) 5.4 0.03 0.03
Consultant reluctant to jeopardize the continuation
of a working relationship with the company.
87 (87%) 66 (74%) 4.3 0.04 0.06
Guarantees of future collaborative projects with the
sponsor are likely to bias an author.
89 (93%) 66 (79%) 7.1 0.008 0.01
doi:10.1371/journal.pone.0026900.t002
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published to date. Such a study of fictitious manuscripts should be
considered the next step in research of this topic.
Our survey also relies on questions about the industry-author
relationships: speakers bureau member and consultant, which
were not further defined in detail. Nevertheless, actual character-
istics of speakers bureaus or consulting arrangements are not
known, uniform, or found in disclosures required by journals.
Ultimately, we expect that the interplay of perceptual influences
and the imprecision in disclosures within our survey mirrors those
faced by reviewers who are presented with actual conflict of
interest disclosures on manuscripts under review. The reported
reviewer perceptions, therefore, may be important influences on
how reviewers assess submitted manuscripts.
Our findings may not generalize to other journals or specialties.
Nevertheless, this particular reviewer population is similar to
reviewers from other journals and specialties [5,11,12], including
the ability of these reviewers to detect deliberate introduced flaws
in a manuscript [9,10,13] [14,15,16,17].
We did not adjust our levels of statistical significance for
multiple comparisons with the Bonferoni correction, which may be
too conservative; readers should interpret our findings in light of
multiple comparisons we made.
Conclusions
Based on our findings, we offer several practices that might help
reviewers and readers better understand the degree and character
of potential bias introduced by financial disclosures:
N Because there is neither evidence nor consensus to
support a specified minimum monetary threshold
below which bias does not exist, the monetary
amount of all financial relationships should be
reported with manuscript submissions. We recom-
mend that all financial relationships should be disclosed
because over one-half of our reviewers believed that any
honorarium would most likely bias the author’s judgment.
Because the percentage of reviewers who held this belief
increased as the specific amount of honorarium increased, we
recommend that the exact monetary amount also be disclosed.
N Lead authors should be required to certify that they
have had unrestricted access to all data and statis-
tical analysis, and the right to publish in accordance
with ICMJE recommendations. Several recent incidents
support the need for adherence to this recommendation. These
incidents exposed that important adverse events were not
reported in publications, and that several authors received
either incomplete data or only the final results tables with no
access to the analysis undertaken or original data set
[18,19,20].
N Because our results raise the concern that reviewers
with personal ties to industry may be vulnerable to
minimizing the possible bias associated with finan-
cial relationships with industry, all reviewers should
disclose any financial ties to industry whether related
to the article under review or not. In support of this
recommendation, other studies suggest that individual physi-
cians may be poor judges of whether a financial relationship
with industry is relevant to the study at hand [18].
Finally, the majority of reviewers surveyed report a high level of
skepticism regarding financial relationships between authors and
industry without a clear or consistent translation of that skepticism
into actions of manuscript assessment and recommendation.
Organizations like ICMJE, COPE, and WAME have all
developed increasingly specific and detailed guidelines on COI
disclosures over the past 10 years, and exhorted all journals to do
the same. Although these increasingly strict and comprehensive
disclosure guidelines have been recommended, our results drive us
to ask whether disclosure alone truly aids reviewers in identifying
potential bias, accounting for the magnitude of its effect and
translating that understanding into action. In addition to the
greater detail about monetary amounts and actual activities
associated with particular disclosures, we propose that research is
needed to better identify the components of study design
vulnerable to COI bias and the specific components of analysis
and result reporting most likely to harbor that bias. Once these
components are identified, journals could develop unique
guidelines to aid reviewers in identifying bias more consistently,
and in more accurately accounting for the effect of that bias in
their manuscript assessment.
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